

**FERRING**

PHARMACEUTICALS

St-Prex, February 25<sup>th</sup>, 2019

Fernando Althabe  
WHO Headquarters Geneva  
Avenue Appia 20,  
1202 Geneva

Dear Mr Althabe,

Ferring welcomes the recent update to the World Health Organisation (WHO) recommendations relating to uterotonics for the prevention of postpartum haemorrhage (PPH), with specific mention of Ferring's heat-stable carbetocin.

We are now seeking registrations for heat-stable carbetocin for the prevention of PPH following all births and are committed to making heat-stable carbetocin available to the public sector in low- and lower middle income countries as a priority following appropriate regulatory approval.

In anticipation of the EML review meeting, 1-5 April 2019, we would like to reinforce Ferring's position and ensure all the information regarding price and availability of the heat-stable carbetocin is accurate and available.

Once approved, the heat-stable formulation of carbetocin will be made available in public-sector health care facilities in low- and lower middle income countries at an affordable and sustainable access price. This price is a subsidized price of \$0.31 +/- 10% per ampoule of 100 µg heat-stable carbetocin (this is comparable to the UNFPA current price of Oxytocin is \$0.27 per unit (10 I.U.)).

This information will also be published in the public domain on our website Ferring.com.

Please let us know if you have any additional questions.

Yours sincerely,



Mike Seckler  
VP Global Marketing Organisation  
Ferring International Center S.A.